OCGNOcugenSigning up patients
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
Dry Age-related Macular Degeneration
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
A key executive is leaving
Since May 14, 2026 · was worth 15, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 237 (planned)
- Started
- Aug 11, 2026
- Main results expected
- Jul 30, 2028
- Fully finished
- Jul 30, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Rate of change (slope) of square root-transformed GA lesion area from baseline to Month 12
Measured over: Month 12
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 2, since 2026-05-14, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT07770828 · record last updated 2026-08-19 · checked 2026-11-09 15:47 UTC